Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci1 , Siena, Italy.
Department of Cardiovascular Disease - AUSL Romagna, Division of Cardiology, Ospedale S. Maria Delle Croci, Viale Randi 5, 48121, Ravenna, Italy.
Heart Fail Rev. 2024 Sep;29(5):1117-1133. doi: 10.1007/s10741-024-10423-9. Epub 2024 Jul 26.
Heart failure (HF) is a clinical syndrome characterized by well-defined signs and symptoms due to structural and/or myocardial functional impairment, resulting in raised intracardiac pressures and/or inadequate cardiac stroke volume at rest or during exercise. This could derive from direct ischemic myocardial injury or other chronic pathological conditions, including valvular heart disease (VHD) and primary myocardial disease. Early identification of HF etiology is essential for accurate diagnosis and initiation of early and appropriate treatment. Thus, the presence of accurate means for early diagnosis of HF symptoms or subclinical phases is fundamental, among which echocardiography being the first line diagnostic investigation. Echocardiography could be performed at rest, to identify overt structural and functional abnormalities or during physical or pharmacological stress, in order to elicit subclinical myocardial function impairment e.g. wall motion abnormalities and raised ventricular filling pressures. Beyond diagnosis of ischemic heart disease, stress echocardiography (SE) has recently shown its unique value for the evaluation of diastolic heart failure, VHD, non-ischemic cardiomyopathies and pulmonary hypertension, with recommendations from international societies in several clinical settings. All these features make SE an important additional tool, not only for diagnostic assessment, but also for prognostic stratification and therapeutic management of patients with HF. In this review, the unique value of SE in the evaluation of HF patients will be described, with the objective to provide an overview of the validated methods for each setting, particularly for HF management.
心力衰竭(HF)是一种临床综合征,其特征为由于结构和/或心肌功能障碍导致的明确的体征和症状,导致静息或运动时心内压升高和/或心搏量不足。这可能源自直接缺血性心肌损伤或其他慢性病理状况,包括瓣膜性心脏病(VHD)和原发性心肌疾病。早期确定 HF 的病因对于准确诊断和尽早开始适当的治疗至关重要。因此,存在准确的方法来早期诊断 HF 症状或亚临床阶段至关重要,其中超声心动图是一线诊断检查。超声心动图可以在静息时进行,以识别明显的结构和功能异常,或在体力或药物应激时进行,以引出亚临床心肌功能障碍,例如壁运动异常和升高的心室充盈压。除了诊断缺血性心脏病外,应激超声心动图(SE)最近在评估舒张性心力衰竭、VHD、非缺血性心肌病和肺动脉高压方面显示出其独特的价值,国际社会在多个临床环境中提出了相关建议。所有这些特征都使 SE 成为一种重要的附加工具,不仅用于诊断评估,还用于 HF 患者的预后分层和治疗管理。在这篇综述中,将描述 SE 在评估 HF 患者中的独特价值,旨在概述每个设置中经过验证的方法,特别是在 HF 管理方面。